TY - JOUR
T1 - Long-term outcomes and toxicities of a large cohort of anal cancer patients treated with dose-painted IMRT per RTOG 0529
AU - Mitra, Devarati
AU - Hong, Theodore S.
AU - Horick, Nora
AU - Rose, Brent
AU - Drapek, Lorraine N.
AU - Blaszkowsky, Lawrence S.
AU - Allen, Jill N.
AU - Kwak, Eunice L.
AU - Murphy, Janet E.
AU - Clark, Jeffrey W.
AU - Ryan, David P.
AU - Cusack, James C.
AU - Bordeianou, Liliana G.
AU - Berger, David L.
AU - Wo, Jennifer Y.
N1 - Publisher Copyright:
© 2017 The Authors on behalf of the American Society for Radiation Oncology
PY - 2017/4
Y1 - 2017/4
N2 - Purpose To describe the outcomes and toxicities of the largest cohort to date of patients with anal squamous cell carcinoma uniformly treated with concurrent chemoradiation using dose-painted intensity modulated radiation therapy (DP-IMRT) according to RTOG 0529. Methods and materials We identified 99 eligible patients with anal cancer who were treated at our institution with definitive chemoradiation using DP-IMRT between 2005 and 2015 per RTOG 0529 dosing guidelines. Primary study endpoints included event-free survival (defined as recurrence, colostomy, or death) and overall survival. Secondary endpoints were treatment duration and acute and late toxicity. Results At a median follow-up of 49 months (range, 2-114 months), 92% of patients had a clinical complete response. Fifteen percent underwent colostomy, including 4 pretreatment colostomies, 6 planned abdominoperineal resections (APRs), 4 salvage APRs, and 1 APR for treatment-related complications. Thirteen patients developed local recurrence, of whom 6 developed synchronous metastatic disease. The 4-year overall survival was 85.8%, and 4-year event-free survival was 75.5%. Median treatment duration was 43 days (range, 10-68 days). The overall rate of non-hematologic grade 3+ acute and grade 2+ late toxicities was 20% and 15%, respectively. Conclusions Long-term outcomes and tolerability were excellent In the largest cohort to date of patients with anal cancer who received DP-IMRT prescribed per RTOG 0529.
AB - Purpose To describe the outcomes and toxicities of the largest cohort to date of patients with anal squamous cell carcinoma uniformly treated with concurrent chemoradiation using dose-painted intensity modulated radiation therapy (DP-IMRT) according to RTOG 0529. Methods and materials We identified 99 eligible patients with anal cancer who were treated at our institution with definitive chemoradiation using DP-IMRT between 2005 and 2015 per RTOG 0529 dosing guidelines. Primary study endpoints included event-free survival (defined as recurrence, colostomy, or death) and overall survival. Secondary endpoints were treatment duration and acute and late toxicity. Results At a median follow-up of 49 months (range, 2-114 months), 92% of patients had a clinical complete response. Fifteen percent underwent colostomy, including 4 pretreatment colostomies, 6 planned abdominoperineal resections (APRs), 4 salvage APRs, and 1 APR for treatment-related complications. Thirteen patients developed local recurrence, of whom 6 developed synchronous metastatic disease. The 4-year overall survival was 85.8%, and 4-year event-free survival was 75.5%. Median treatment duration was 43 days (range, 10-68 days). The overall rate of non-hematologic grade 3+ acute and grade 2+ late toxicities was 20% and 15%, respectively. Conclusions Long-term outcomes and tolerability were excellent In the largest cohort to date of patients with anal cancer who received DP-IMRT prescribed per RTOG 0529.
UR - http://www.scopus.com/inward/record.url?scp=85016601713&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85016601713&partnerID=8YFLogxK
U2 - 10.1016/j.adro.2017.01.009
DO - 10.1016/j.adro.2017.01.009
M3 - Article
C2 - 28740921
AN - SCOPUS:85016601713
SN - 2452-1094
VL - 2
SP - 110
EP - 117
JO - Advances in Radiation Oncology
JF - Advances in Radiation Oncology
IS - 2
ER -